BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 11545191)

  • 1. Diagnostic usefulness of FDG PET for pancreatic mass lesions.
    Koyama K; Okamura T; Kawabe J; Nakata B; Chung KH; Ochi H; Yamada R
    Ann Nucl Med; 2001 Jun; 15(3):217-24. PubMed ID: 11545191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
    Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
    J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
    Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
    Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accuracy of 18F-FDG PET/CT, Multidetector CT, and MR Imaging in the Diagnosis of Pancreatic Cysts: A Prospective Single-Center Study.
    Kauhanen S; Rinta-Kiikka I; Kemppainen J; Grönroos J; Kajander S; Seppänen M; Alanen K; Gullichsen R; Nuutila P; Ovaska J
    J Nucl Med; 2015 Aug; 56(8):1163-8. PubMed ID: 26045314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions.
    Tian R; Su M; Tian Y; Li F; Li L; Kuang A; Zeng J
    Skeletal Radiol; 2009 May; 38(5):451-8. PubMed ID: 19205695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature.
    Guan ZW; Xu BX; Wang RM; Sun L; Tian JH
    Hell J Nucl Med; 2013; 16(2):97-102. PubMed ID: 23687644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
    Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
    Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
    J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET evaluation of fatty tumors in the extremity: possibility of using the standardized uptake value (SUV) to differentiate benign tumors from liposarcoma.
    Suzuki R; Watanabe H; Yanagawa T; Sato J; Shinozaki T; Suzuki H; Endo K; Takagishi K
    Ann Nucl Med; 2005 Dec; 19(8):661-70. PubMed ID: 16444991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
    Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
    Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of MR imaging and FDG-PET/CT in the differential diagnosis of benign and malignant vertebral compression fractures.
    Cho WI; Chang UK
    J Neurosurg Spine; 2011 Feb; 14(2):177-83. PubMed ID: 21214309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas.
    Nakamoto Y; Higashi T; Sakahara H; Tamaki N; Kogire M; Doi R; Hosotani R; Imamura M; Konishi J
    Cancer; 2000 Dec; 89(12):2547-54. PubMed ID: 11135214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between apparent diffusion coefficients on diffusion-weighted MRI and standardized uptake value on FDG-PET/CT in pancreatic adenocarcinoma.
    Sakane M; Tatsumi M; Kim T; Hori M; Onishi H; Nakamoto A; Eguchi H; Nagano H; Wakasa K; Hatazawa J; Tomiyama N
    Acta Radiol; 2015 Sep; 56(9):1034-41. PubMed ID: 25267921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solid splenic masses: evaluation with 18F-FDG PET/CT.
    Metser U; Miller E; Kessler A; Lerman H; Lievshitz G; Oren R; Even-Sapir E
    J Nucl Med; 2005 Jan; 46(1):52-9. PubMed ID: 15632034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective evaluation of solitary thyroid nodule on 18F-FDG PET/CT and high-resolution ultrasonography.
    D'Souza MM; Marwaha RK; Sharma R; Jaimini A; Thomas S; Singh D; Jain M; Bhalla PJ; Tripathi M; Tiwari A; Mishra A; Mondal A; Tripathi RP
    Ann Nucl Med; 2010 Jun; 24(5):345-55. PubMed ID: 20373060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
    Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
    Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: a prospective study.
    Sperti C; Pasquali C; Decet G; Chierichetti F; Liessi G; Pedrazzoli S
    J Gastrointest Surg; 2005 Jan; 9(1):22-8; discussion 28-9. PubMed ID: 15623441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additional value of FDG PET/CT to contrast-enhanced CT in the differentiation between benign and malignant intraductal papillary mucinous neoplasms of the pancreas with mural nodules.
    Takanami K; Hiraide T; Tsuda M; Nakamura Y; Kaneta T; Takase K; Fukuda H; Takahashi S
    Ann Nucl Med; 2011 Aug; 25(7):501-10. PubMed ID: 21537945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
    Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
    Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.